ОПЫТ ПРИМЕНЕНИЯ ТИОКТОВОЙ КИСЛОТЫ НА ПОКАЗАТЕЛИ  ВЫРАЖЕННОСТИ ДИАБЕТИЧЕСКОЙ ПОЛИНЕВРОПАТИИ  В ЗАВИСИМОСТИ ОТ ПРОДОЛЖИТЕЛЬНОСТИ САХАРНОГО ДИАБЕТА

M.S. Moldobaeva; N.M. Esengeldieva

doi:10.54890/.v3i3.186

M.S. Moldobaeva N.M. Esengeldieva

DOI:

https://doi.org/10.54890/.v3i3.186

Abstract

Summary. Objective: To study the effectiveness of the use of thioctic acid (ТА) on subjective and objective indicators of the severity of distal diabetic polyneuropathy (DPN) depending on the duration of the disease in complex treatment in patients with type 2 diabetes mellitus (DM 2): 42 patients with type 2 diabetes in the main group, who treated with ТА (Tiocton) of Rompharm Company and 24 patients in the control group, who did not treat with ТА. Duration of DM 2: the 1st group from 5 to 10 years and the 2nd group over 10 years. The use of ТА in patients with type 2 diabetes with DPN has a positive effect in the form of a reduction in the severity of subjective and objective signs, more in group with duration of DM 2 over 10 years and in the control group a slight decrease only subjective signs. To obtain the stability of the positive effect of subjective and objective signs of DPN in DM 2 from the use of preparations of ТА for more than 1 month, it is necessary to continue the use of ТА on an outpatient basis.

Keywords:

diabetes mellitus, diabetic polyneuropathy, duration, thioctic acid.

References

1. NCD Risk Factor Collaboration (NCD-RisC. Worldwide trends in diabetes since 1980: a pooled analysis o f 751 population-based studies with 4.4 million participants // Lancet-2016.-387(10027)-P. 1513-1530.

2. Атлас IDF-издание 8-e, 2017.

3. Центр Электронного Здравоохранения np М3 КР [Электронный ресурс].- Режим доступа: http://cez.med.kg/, свободный.-Яз. русс. кырг.

4. Hosseini, A. Diabetic neuropathy and oxidative stress: therapeutic perspectives A. Hosseini, M Abdollahi // Oxidative Medicine and Cellular Longevity.-2013,- Vol.2013-P. 15.

5. Boulton, A.J. Diabetic neuropathyA.J. Boulton, R.A. Malik / / Med. Clin. North Am .-l998.-82(4).-P. 909-929.

6. 10-year follow-up o f intensive glucose control in type 2 diabetes [R.R. Holman, S.K. Paul, M.A. Bethel el al.J // The New England Journal of Medicine.-2008.- Vol. 359.-P. 1577-1589.

7. UKPDS: Intensive blood glucose with sulphonylureas or insulin compared with conventional treatment and risk o f complications in patients with type 2 diabetes 7 Lancet.-1998.-Vol.352, P. 837.

8. DCCT (The Diabetes Control and Complications Trial Research Group). The effect o f intensive treatment o f diabetes on the development and progression o f longterm complications in insulin-dependent diabetes mellitus // N Engl J Med. -1993. 329.-P. 977-986.

9. Brownlee, M. The pathobiology o f diabetic complications. A unifying mechanism / M. Brownlee Diabetes-2005.-Vol. 5, no.6.-P. 1615-1625.

10. Dyck, P.J. The prevalence by staged severity o f various types o f diabetic neuropathy, retinopathy and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study P.J. Dyck, K.M. Katz, J.L. Karnes // Neurology.-1993.- Vol. 43.-P. 817-824.

11. Reed, L.J. Crystalline a-lipoic acid: a catalytic agent associated with pyruvate dehydrogenase L.J. Reed, B.G. Debusk, I.C.Gunsalus // Science.- 1951.-Vol. 114, no. 2952.-P. 93-94.

12. Ziegler, D. Treatment o f symptomatic diabetic polyneuropathy with antioxidant a-lipoic acid: a metaanalysis D. Ziegler, H. Nowak, P. Kemplert Diabet M ed.-2004- Vol. 21.-P. 114-121.

13. Ziegler, D. Oral treatment with al- pha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial D. Ziegler, A. Ametov, A. Barinov // Diabet Care.-2006. -Vol. 29.-P. 2365-2370.

14. Tesfaye, S. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation o f severity, and treatments S. Tesfaye, A.J.M. Boulton, P.J. Dyck // Diabetes Care.-2010.-Vol. 33(10)-P. 2285-2293.

15. M cllduff C.E. Critical appraisal of the use o f alpha lipoic acid (thioctic acid) in the treatment of symptomatic diabetic polyneuropathy C.E. Mcllduff, S.B. Rutkove // Ther. Clin. Risk Manag.-2011.- Vol. 7.-P. 377-385.

16. Mirza, N. Alpha-lipoic acid fo r diabetic peripheral neuropathy (Protocol) / N. Mirza, D.R. Cornblath, S. Hasan // Cochrane Database o f Systematic Review s.- 2005.-no. 4.

17. Alpha-lipoic acid fo r diabetic peripheral neuropathy (Protocol) [C. Baicus, A. Purcarea, E. von Elm et al.] // The Cochrane Collaboration.-2018.

18. Ziegler, D. а-Lipoic acid in the treatment o f diabetic polyneuropathy in Germany: Current evidence from clinical trials D. Ziegler, M. Reljanovic, H. Mehnert // Exp Clin Endocrinol Diabetes.-1999.-107.-P. 421-430.